- ImmunityBio has finally submitted the Anktiva (N-803) and BCG combination BLA in NMIBC ahead of the final clinical results presentation at ASCO.
- The company is still moving forward with multiple cancer and infectious disease programs with Anktiva. An FDA approval would improve the outlook for these programs.
- IBRX has been punished over the past 12 months falling roughly 76%. The company’s market cap is only ~$1.39B, which I believe is a steal considering the company’s long-term potential.
- I am looking to switch gears in re-amassing a hefty IBRX position. I discuss my strategy for the remainder of 2022.
For further details see:
ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission